NCI Director Sharpless to step down; a doctor's cancer research become painfully real

Ned Sharpless spent nearly five years leading the roughly $7 billion biomedical research agency, ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        NIH's cancer chief, Ned Sharpless, to step down By Lev Facher DOULIERY/AFP via Getty Images Sharpless, who spent nearly five years leading the National Cancer Institute within the NIH, will step down at the end of April, he told STAT. Read More STAT+: When a dire text message interrupted his talk, this doctor's cancer research became painfully real By Jonathan Wosen Sandy Huffaker for STAT UC San Diego oncologist Scott Lippman has spent decades treating head and neck cancer patients and trying to understand how their tumors form. Read More STAT+: Roche anti-TIGIT cancer immunotherapy fails in first late-stage clinical trial By Adam Feuerstein SEBASTIEN BOZON/AFP via Getty Images The result is the first from a group of late-stage clinical trials that Roche is conducting for its anti-TIGIT drug called tiragolumab. Read More Sponsor content by NATERA How can personalized ctDNA testing enhance surveillance for patients with high risk breast cancer? Personalized testing for circulating tumor DNA (ctDNA) can help catch recurrence early in post-treatment surveillance for high risk breast cancer patients, potentially improving their outcomes. Serial monitoring for presence of ctDNA after primary treatment can inform follow-up care. In a clinical study, a ctDNA assay custom built from each patient's unique tumor detected molecular residual disease (MRD) up to two years ahead of imaging and other indicators. Learn more. STAT+: The biotech scorecard for the second quarter: 21 stock-moving events to watch By Adam Feuerstein Ryan Pierse/Getty Images There's plenty to watch out for in the months ahead, including a readout from Alnylam Pharmaceuticals and another from Roche. Read More Tuesday, April 5, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser